Please login to the form below

Not currently logged in
Email:
Password:

sodium zirconium cyclosilicate

This page shows the latest sodium zirconium cyclosilicate news and features for those working in and with pharma, biotech and healthcare.

Real-world data finds patients feel better on Entresto, says Novartis

Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

Latest news

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    Lokelma (sodium zirconium cyclosilicate or ZS-9) has been cleared by the FDA as an oral treatment for hyperkalaemia (elevated potassium levels) in adults, a potentially life-threatening condition caused by

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    Lokelma (sodium zirconium cyclosilicate or ZS-9) has been approved for adults with hyperkalaemia, a potentially life-threatening condition which can cause cardiac arrest and muscle paralysis, allowing it to finally

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    However, there’s potential competition on the horizon from AstraZeneca, which has a positive opinion the Committee for Medicinal Products for Human Use (CHMP) for its hyperkalaemia drug Lokelma (sodium zirconium ... cyclosilicate) in February.

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    Lokelma (sodium zirconium cyclosilicate) is a potassium-binding compound designed to reduce excessive levels of serum potassium by drawing it into the gastrointestinal tract.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics